Home/Pipeline/aplitabart (IGM-8444)

aplitabart (IGM-8444)

Solid tumors

Phase 1Active

Key Facts

Indication

Solid tumors

Phase

Phase 1

Status

Active

Company

IGM Biosciences

About IGM Biosciences

IGM Biosciences is a public, clinical-stage biotech company with a differentiated focus on developing engineered IgM antibodies, a class distinct from the industry-standard IgG. Its lead asset, imvotamab (CD20xCD3), is a bispecific T-cell engager in Phase 2 trials for B-cell malignancies, while other programs target solid tumors and autoimmune conditions. The company's core thesis is that its IgM platform can generate therapeutics with potentially superior binding strength and unique biological effects compared to existing modalities, though this novel approach carries significant clinical and commercial validation risk.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Inflammatory Diseases

Other Solid tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active